Latest INZY reports update at 2024-05-07: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Inozyme Pharma INZY

$ 4.7 -0.63%

Inozyme Pharma Financial Statements 2011-2024 | INZY

Annual Financial Statements Inozyme Pharma

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	297 M	102 M	161 M	381 M	-	-	-	-	-	-	-	-	-
Shares	51.8 M	37.8 M	23.6 M	18.1 M	-	-	-	-	-	-	-	-	-
Historical Prices	5.72	2.69	6.82	20.6	-	-	-	-	-	-	-	-	-
Net Income	-71.2 M	-67.1 M	-56.6 M	-56.4 M	-19.7 M	-6.96 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-75.6 M	-68.7 M	-56.6 M	-57 M	-20.8 M	-	-	-	-	-	-	-	-
Interest Expense	3.33 M	262 K	-189 K	247 K	-24 K	-	-	-	-	-	-	-	-
EBITDA	-74.8 M	-68 M	-56 M	-56.8 M	-20.7 M	-11.6 M	-	-	-	-	-	-	-
Operating Expenses	75.6 M	68.7 M	56.6 M	57 M	20.8 M	11.6 M	-	-	-	-	-	-	-
General and Administrative Expenses	20.8 M	20.8 M	18.9 M	10.5 M	4.59 M	3.49 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Inozyme Pharma

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	61.8 M	61.8 M	56.8 M	44.9 M	43.7 M	40.4 M	43.7 M	39.7 M	23.7 M	23.7 M	23.6 M	23.5 M	23.4 M	23.4 M	18.1 M	1.25 M	1.21 M	1.2 M	1.2 M	1.17 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-23.3 M	-	-16.6 M	-15.6 M	-17.4 M	-	-16.4 M	-15.3 M	-16.9 M	-	-14.3 M	-12.5 M	-11 M	-	56.4 M	-56.4 M	-56.4 M	-	-19.7 M	-19.7 M	-4.97 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-24.3 M	-	-18.1 M	-16.4 M	-18.4 M	-	-16.9 M	-15.4 M	-16.8 M	-	-14.3 M	-12.7 M	-11 M	-	-28.3 M	-9.55 M	-7.91 M	-	-4.32 M	-4.55 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	1.32 M	-	20 K	-28 K	328 K	-	-197 K	-191 K	-105 K	-	-65 K	57 K	-141 K	-	157 K	4 K	-3 K	-	-3 K	-14 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-24.2 M	-	-	-	-18.2 M	-	-16.7 M	-15.2 M	-16.7 M	-	-14.1 M	-12.5 M	-10.8 M	-	-28.3 M	-9.52 M	-7.88 M	-	-4.3 M	-4.53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	24.3 M	-	18.1 M	16.4 M	18.4 M	-	16.9 M	15.4 M	16.8 M	-	14.3 M	12.7 M	11 M	-	28.3 M	9.55 M	7.91 M	-	4.32 M	4.55 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	5.23 M	-	4.73 M	4.73 M	6.51 M	-	4.72 M	5.38 M	5.02 M	-	4.92 M	4.44 M	4.37 M	-	3.14 M	1.67 M	1.5 M	-	1 M	1.06 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency